Multiple sclerosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Template:Multiple sclerosis}} | {{Template:Multiple sclerosis}} | ||
{{CMG}}; {{AE}} {{Fs}} | |||
== Overview == | |||
Given the [[morbidity]] and [[mortality]] associated with multiple sclerosis, as well as the high cost of treating the acute attacks and [[disability]] of [[MS]] disease, treatment with [[Interferon beta-1a|IFN β-1a]] [[Subcutaneous|SC]] injection, [[Interferon beta-1b|IFNβ-1b]] [[Subcutaneous|SC injection]], and [[glatiramer acetate]] is relatively [[Cost-effectiveness|cost-effective]]. Life time [[treatment]] of multiple sclerosis [[patients]] can cost as much as 2.2 million US dollar. Controlling acute attack can reduce the economic burden of [[MS]] [[disease]]. | |||
==Cost effectiveness== | ==Cost effectiveness== | ||
Given the [[morbidity]] and [[mortality]] associated with multiple sclerosis | * Given the [[morbidity]] and [[mortality]] associated with multiple sclerosis, as well as the high cost of treating the acute attacks and [[disability]] of [[MS]] disease, treatment with [[Interferon beta-1a|IFN β-1a]] [[Subcutaneous|SC]] injection, [[Interferon beta-1b|IFNβ-1b]] [[Subcutaneous|SC injection]], and [[glatiramer acetate]] is relatively [[Cost-effectiveness|cost-effective]].<ref name="pmid19739877">{{cite journal |vauthors=Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM |title=Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis |journal=J Manag Care Pharm |volume=15 |issue=7 |pages=543–55 |date=September 2009 |pmid=19739877 |doi=10.18553/jmcp.2009.15.7.543 |url=}}</ref> | ||
* Life time [[treatment]] of multiple sclerosis patients can cost as much as 2.2 million US dollar.<ref name="pmid9839302">{{cite journal |vauthors=Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED |title=A comprehensive assessment of the cost of multiple sclerosis in the United States |journal=Mult. Scler. |volume=4 |issue=5 |pages=419–25 |date=October 1998 |pmid=9839302 |doi=10.1177/135245859800400504 |url=}}</ref> | |||
* Controlling acute attack can reduce the economic burden of [[MS]] [[disease]].<ref name="pmid15794399">{{cite journal |vauthors=Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT |title=Cost of multiple sclerosis by level of disability: a review of literature |journal=Mult. Scler. |volume=11 |issue=2 |pages=232–9 |date=April 2005 |pmid=15794399 |doi=10.1191/1352458505ms1137oa |url=}}</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
[[Category:Neurological disorders]] | [[Category:Neurological disorders]] | ||
[[Category: | [[Category:Multiple sclerosis]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Orthopedics]] | [[Category:Orthopedics]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 22:47, 29 July 2020
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis cost-effectiveness of therapy |
|
Multiple sclerosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Multiple sclerosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Given the morbidity and mortality associated with multiple sclerosis, as well as the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective. Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar. Controlling acute attack can reduce the economic burden of MS disease.
Cost effectiveness
- Given the morbidity and mortality associated with multiple sclerosis, as well as the high cost of treating the acute attacks and disability of MS disease, treatment with IFN β-1a SC injection, IFNβ-1b SC injection, and glatiramer acetate is relatively cost-effective.[1]
- Life time treatment of multiple sclerosis patients can cost as much as 2.2 million US dollar.[2]
- Controlling acute attack can reduce the economic burden of MS disease.[3]
References
- ↑ Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM (September 2009). "Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis". J Manag Care Pharm. 15 (7): 543–55. doi:10.18553/jmcp.2009.15.7.543. PMID 19739877.
- ↑ Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (October 1998). "A comprehensive assessment of the cost of multiple sclerosis in the United States". Mult. Scler. 4 (5): 419–25. doi:10.1177/135245859800400504. PMID 9839302.
- ↑ Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT (April 2005). "Cost of multiple sclerosis by level of disability: a review of literature". Mult. Scler. 11 (2): 232–9. doi:10.1191/1352458505ms1137oa. PMID 15794399.